健倍苗苗(02161.HK)委任中國平安資本為新合規顧問
格隆匯 4 月 30日丨健倍苗苗(02161.HK)宣佈,由於高通融資有限公司("高通")的主要人員變動將削弱高通向公司提供滿意的合規顧問服務的能力,公司與高通已相互同意終止雙方所訂立日期為2020年12月4日的合規顧問協議。該終止將於2021年4月30日生效。
進一步宣佈,中國平安資本(香港)有限公司("中國平安資本")已根據上市規則第3A.27條的要求獲委任為公司的新合規顧問,任期由2021年4月30日起,至公司就根據上市規則第3A.19條就截至2022年3月31日止年度的財務業績遵照上市規則第13.46條之日止;或直至公司與中國平安資本訂立的合規顧問協議根據其條款終止(以較早者為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.